Volume 70, Issue 4, Pages (October 2016)

Slides:

Advertisements

Similar presentations

Volume 69, Issue 5, Pages (May 2016)

Advertisements

Volume 71, Issue 5, Pages (May 2017)

Volume 68, Issue 6, Pages (December 2015)

Volume 60, Issue 5, Pages (November 2011)

Volume 70, Issue 3, Pages (September 2016)

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 Silke Gillessen, Gerhardt.

Volume 60, Issue 2, Pages (August 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Volume 27, Issue 4, Pages (December 2016)

Volume 70, Issue 6, Pages (December 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Fred Saad European Urology Supplements

Volume 52, Issue 5, Pages (November 2007)

Volume 73, Issue 2, Pages (February 2018)

Volume 60, Issue 2, Pages (August 2011)

Volume 67, Issue 4, Pages (April 2015)

Volume 68, Issue 4, Pages (October 2015)

Volume 66, Issue 5, Pages (November 2014)

Volume 49, Issue 2, Pages (February 2006)

Volume 53, Issue 5, Pages (May 2008)

Volume 69, Issue 1, Pages (January 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 51, Issue 4, Pages (April 2007)

Managing Nonmetastatic Castration-resistant Prostate Cancer

Volume 68, Issue 1, Pages (July 2015)

Volume 52, Issue 4, Pages (October 2007)

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology Philipp.

Volume 70, Issue 5, Pages (November 2016)

Volume 71, Issue 2, Pages (February 2017)

Volume 68, Issue 4, Pages (October 2015)

Volume 65, Issue 5, Pages (May 2014)

Volume 74, Issue 1, Pages (July 2018)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 70, Issue 5, Pages (November 2016)

Volume 70, Issue 4, Pages (October 2016)

Volume 66, Issue 3, Pages (September 2014)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 66, Issue 5, Pages (November 2014)

Volume 70, Issue 5, Pages (November 2016)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 63, Issue 3, Pages (March 2013)

Volume 74, Issue 2, Pages (August 2018)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 71, Issue 2, Pages (February 2017)

Volume 50, Issue 5, Pages (November 2006)

Volume 73, Issue 5, Pages (May 2018)

The Importance of Testosterone Control in Prostate Cancer

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 70, Issue 6, Pages (December 2016)

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 74, Issue 3, Pages (September 2018)

Volume 70, Issue 1, Pages (July 2016)

Volume 75, Issue 3, Pages (March 2019)

Volume 71, Issue 4, Pages (April 2017)

Volume 69, Issue 5, Pages (May 2016)

European Urology Oncology

Volume 68, Issue 5, Pages (November 2015)

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Volume 53, Issue 6, Pages (June 2008)

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Manfred Wirth, Peter Iversen, David McLeod, William See

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis Sarah Burdett, Liselotte M. Boevé,

Volume 76, Issue 1, Pages (July 2019)

Volume 54, Issue 1, Pages (July 2008)

Presentation transcript:

Volume 70, Issue 4, Pages 675-683 (October 2016) The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Christopher P. Evans, Celestia S. Higano, Thomas Keane, Gerald Andriole, Fred Saad, Peter Iversen, Kurt Miller, Choung-Soo Kim, Go Kimura, Andrew J. Armstrong, Cora N. Sternberg, Yohann Loriot, Johann de Bono, Sarah B. Noonberg, Hank Mansbach, Suman Bhattacharya, Frank Perabo, Tomasz M. Beer, Bertrand Tombal European Urology Volume 70, Issue 4, Pages 675-683 (October 2016) DOI: 10.1016/j.eururo.2016.03.017 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Kaplan–Meier estimates of (A) radiographic progression-free survival and (B) overall survival in the nonvisceral and visceral subgroups. CI=confidence interval; HR=hazard ratio; NYR=not yet reached. European Urology 2016 70, 675-683DOI: (10.1016/j.eururo.2016.03.017) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 2 Kaplan–Meier estimates of (A) radiographic progression-free survival and (B) overall survival by number of bone metastases at screening (<4 vs ≥4). CI=confidence interval; HR=hazard ratio; mets=metastases; NYR=not yet reached. European Urology 2016 70, 675-683DOI: (10.1016/j.eururo.2016.03.017) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 3 Kaplan–Meier estimates of (A) radiographic progression-free survival and (B) overall survival in the subgroup of patients with lymph node only disease. CI=confidence interval; HR=hazard ratio; NYR=not yet reached. European Urology 2016 70, 675-683DOI: (10.1016/j.eururo.2016.03.017) Copyright © 2016 European Association of Urology Terms and Conditions